Scrip
US buys 10,000 courses of BioCryst's peramivir
06 November 2009
Sue Sutter
Please Login to read the full article.
06 November 2009
Sue Sutter
sue.sutter@informa.com
BioCryst Pharmaceuticals has shipped 10,000 treatment courses of its intravenous antiviral peramivir to the US health and human services (HHS) department under a $22.5 million contract aimed at countering the toll of H1N1 influenza.
The order came less than two weeks after the FDA authorised...
Please Login to read the full article.
RELATED CONTENT
NEWS
- US moves closer to allowing emergency use of peramivir for H1N1
- US FDA authorises BioCryst's IV peramivir for emergency H1N1 use – updated
- BioCryst signs two more non-US partnerships for peramivir
- US FDA reinforces mandatory adverse event reporting for BioCryst's IV peramivir
COMMENT
Other Informa Comment
FEATURES
- Interview: European Medicines Agency gets serious about its global strategy
- Anti-obesity drugs: an inventor's perspective
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
